Special Organic Chemistry Seminar
Noyes 153 (J. Holmes Sturdivant Lecture Hall)
Current and Potential Treatments of Systolic Heart Failure: the Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin
Bradley P. Morgan,
Cytokinetics, Inc.,
"Current and Potential Treatments of Systolic Heart Failure: the Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin," Bradley P. Morgan, Cytokinetics, Inc.
For more information, please contact Arleen (Lynne) Martinez by phone at 4004 or by email at [email protected].
Event Series
Special Organic Chemistry Seminar Series